Full-Time

Histotechnologist

Confirmed live in the last 24 hours

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$30 - $36Hourly

+ Incentive Compensation + Restricted Stock Units

Junior, Mid

Company Historically Provides H1B Sponsorship

Chicago, IL, USA

The expected salary range is applicable if the role is performed from Illinois.

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary

You match the following Tempus's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • HT or HTL Certification preferred
  • Associates or Bachelor's Degree
  • Familiarity with Leica equipment, manual microtomes, both Leica and Roche automated IHC staining instruments
  • Knowledge of CAP regulations
  • Experience with pathology laboratory SOPs and protocols
  • Comfort with laboratory safety and training
  • Demonstrates problem solving skills in the laboratory
  • Good communication and organization skills
Responsibilities
  • Preparation of both unstained and routine hematoxylin and eosin stained slides from formalin fixed paraffin embedded tissue blocks
  • Maintain laboratory equipment and record maintenance regularly
  • Approach work with safety and diligence and follow safety requirements of the laboratory
  • Perform routine workflows without specific guidance
  • Reliably produce quality finished product
  • Assist in the development of standard operating procedures for new instruments and products
  • Collaborate with other members of the Tempus Labs team
  • Utilize microtome, water bath, automated stainer, automated coverslipper, tissue processors, and embedding centers
  • Collaborate with in-house pathologists for slide quality review
  • Ability to cut frozen sections using a cryostat
  • Track work completed using a custom Laboratory Information Management System (LIMS)
  • Work collaboratively with other members of the Histology team to accomplish daily cutting and staining deadlines

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus also conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Unlike many competitors, Tempus combines extensive data analysis with a focus on personalized medicine, aiming to improve care and treatment options for patients.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$894.9M

Headquarters

Chicago, Illinois

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus' AI platform aids in personalized cancer treatment and drug development.
  • The Olivia app empowers patients with AI-driven health management tools.
  • Partnerships with firms like Genialis expand Tempus' diagnostic capabilities.

What critics are saying

  • Over-reliance on AI may lead to misinterpretation of medical data.
  • Data privacy concerns arise with the Olivia app's extensive health system integration.
  • Regulatory challenges may hinder the global rollout of Tempus' xT CDx test.

What makes Tempus unique

  • Tempus uses AI to provide personalized treatment insights for cancer patients.
  • Their platform integrates clinical and molecular data for precision medicine.
  • Tempus collaborates with biotech firms to enhance drug development and diagnostics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
Hit Consultant
Feb 21st, 2025
Stemline Therapeutics To Deploy Tempus Next’S Ai-Enabled Care Pathway Intelligence Platform

Stemline Therapeutics to Deploy Tempus Next’s AI-Enabled Care Pathway Intelligence Platform. by Fred Pennic 02/21/2025 Leave a Comment. What You Should Know: – Tempus, a provider of AI-driven precision medicine, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group announced a new collaboration to improve the use of ESR1 testing in metastatic breast cancer (mBC). – The partnership will leverage Tempus’ Next platform, an AI-enabled care pathway intelligence tool, to help clinicians determine when ESR1 testing may be appropriate for their patients.Challenges in ESR1 TestingESR1 mutations are a critical factor in the progression of ER+/HER2- mBC, a common type of breast cancer. Up to 50% of patients with this type of cancer can develop ESR1 mutations after prior endocrine therapy. Recognizing this, the American Society of Clinical Oncology (ASCO) recommends ESR1 mutation testing at each disease progression. Tempus Next: Guiding Clinical DecisionsTempus’ Next platform will analyze clinical data from mBC patients and notify clinicians when ESR1 testing is missing at disease progression

ETF Daily News
Feb 15th, 2025
Apollon Wealth Management LLC Makes New $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM)

Apollon Wealth Management LLC makes new $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM).

Money Morning
Feb 14th, 2025
Nancy Pelosi's Favorite AI Stock Rising Again After 13% Surge

Tempus announced yesterday that it was collaborating with the nonprofit Institute for Follicular Lymphoma Innovation to develop treatment options for patients with the disease.

Medical Device Network
Feb 13th, 2025
Artera partners with Tempus to expand AI cancer test access

Currently connected to more than 50% of all oncologists practising in the US, Chicago-based Tempus will work with Artera on an exclusive basis to commercialise the latter's ArteraAI prostate test.

TipRanks
Feb 13th, 2025
Tempus AI enters collaboration with Institute for Follicular Lymphoma Innovation

Tempus AI (TEM) announced a new collaboration with the Institute for Follicular Lymphoma Innovation.